AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
New drug application approval for GLUBES - Fixed dose combination tablet of a rapid-acting insulin secretagogue and improving agent for postprandial hyperglycemia.
On 22 Apr 2011, Kissei Pharmaceutical Co Ltd announced that a New Drug Application for GLUBES, a fixed dose combination tablet of a rapid-acting insulin secretagogue (mitiglinide calcium hydrate, hereinafter "mitiglinide") and an improving agent for postprandial hyperglycemia (voglibose), was approved by the Ministry of Health, Labour and Welfare (Japan). GLUBES approved today for treatment of type 2 diabetes is a fixed dose combination tablet with mitiglinide (Japanese brand name: Glufast) which was a rapid short acting form insulin secretagogue originally developed by Kissei, and with voglibose which was an improving agent for postprandial hyperglycemia. This combination tablet was …
-
- Patient satisfaction with once-daily dosing of HIV fixed-dose combination...
-
News wire article from: Asia Africa Intelligence Wire
July 27, 2005
700+ words
-
- Olmesartan/amlodipine combination tablet approved in Germany: Daiichi Sankyo.
-
News wire article from: Chemical Business Newsbase
November 24, 2008
700+ words
-
- Takeda submits NDA for fixed-dose combination of Actos and SU.
-
News wire article from: Chemical Business Newsbase
August 10, 2009
700+ words
-
- Exforge to be Novartis' next mainstay product.
-
News wire article from: Chemical Business Newsbase
April 12, 2010
700+ words
-
- Takeda launches three new products aiming at combined sales of Yen 10 bn in...
-
News wire article from: Chemical Business Newsbase
June 28, 2010
700+ words
